Frontlight ResearchEarly access
Fatty liver disease (MASLD/MASH) trials in Belgium
13 of 17 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 18 November 2026. Ask the study team whether a trial fits you.
- Phase 3Taking peopleA Study Evaluating Efruxifermin in Subjects With Compensated Cirrhosis Due to NASH/MASH
- Where
- Brussels, Edegem
- Age
- 18 years to 80 years
- People
- 2,150 worldwide
- Run by
- Akero Therapeutics, Inc
See details and how to joinNCT06528314 - Phase 3Taking peopleLIVERAGE™ - Cirrhosis: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Cirrhosis
- Where
- Anderlecht, Edegem, Genk, Liège
- Age
- 18 years and over
- People
- 1,590 worldwide
- Run by
- Boehringer Ingelheim
See details and how to joinNCT06632457 · EU 2024-513741-36-00 - Phase 3Taking peopleLIVERAGE™: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Moderate or Advanced Liver Fibrosis
- Where
- Anderlecht, Edegem, Genk, Gent, Leuven, Liège, Namur, Roeselare, Sint-Lambrechts-Woluwe
- Age
- 18 years and over
- People
- 1,800 worldwide
- Run by
- Boehringer Ingelheim
See details and how to joinNCT06632444 · EU 2024-513739-25-00 - Phase 3Taking peopleA Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Efruxifermin in Subjects with Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH)/Metabolic Dysfunction-Associated Steatohepatitis (MASH)
- Where
- Anderlecht, Edegem, Gent
- Age
- 18 years and over
- People
- 205 worldwide
- Run by
- Akero Therapeutics Inc.
See details and how to join2024-512895-36-00 - Phase 3Taking peopleA Study Evaluating the Efficacy and Safety of Pegozafermin in Participants With MASH and Fibrosis (ENLIGHTEN-Fibrosis)
- Where
- Anderlecht, Brussels, Edegem, Genk, Gent, Jette
- Age
- 18 years to 80 years
- People
- 1,350 worldwide
- Run by
- Hoffmann-La Roche
See details and how to joinNCT06318169 · EU 2023-509912-27-00 - Phase 3Taking peopleA Study to Evaluate the Efficacy and Safety of Pegozafermin in Participants With Compensated Cirrhosis Due to MASH
- Where
- Anderlecht, Edegem, Genk, Gent, Jette, Roeselare, Sint-Lambrechts-Woluwe
- Age
- 18 years to 75 years
- People
- 1,800 worldwide
- Run by
- Hoffmann-La Roche
See details and how to joinNCT06419374 · EU 2023-510395-31-00 - Phase 3Not yet taking people in BelgiumA pivotal clinical study to investigate the safety and efficacy of efimosfermin compared with placebo in adult participants with compensated cirrhosis due to Metabolic dysfunction-associated steatohepatitis (MASH)
- Where
- Anderlecht, Edegem, Gent, Liège, Sint-Lambrechts-Woluwe
- Age
- 18 years and over
- People
- 382 worldwide
- Run by
- Glaxosmithkline Research & Development Limited
See details and how to join2026-525755-82-00 - Phase 3Not yet taking people in BelgiumA study to investigate safety and efficacy of efimosfermin compared with placebo in adult participants with compensated cirrhosis (stage F4 fibrosis) due to MASH (NEBULA-2)
- Where
- Anderlecht, Edegem, Gent, Liège, Sint-Lambrechts-Woluwe
- Age
- 18 years and over
- People
- 69 worldwide
- Run by
- Glaxosmithkline Research & Development Limited
See details and how to join2026-525757-37-00 - Phase 3Taking peopleA Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)
- Where
- Brussels, Edegem, Ghent, Kortrijk, Ostend, Roeselare, Sint-Niklaas
- Age
- 18 years and over
- People
- 4,500 worldwide
- Run by
- Eli Lilly and Company
See details and how to joinNCT07165028 · EU 2025-522674-36-00 - Phase 3Taking peopleA Clinical Study to Investigate the Safety and Tolerability of Efimosfermin Alfa Injection in Participants With Known or Suspected F2- or F3-stage MASH
- Where
- Anderlecht, Edegem, Gent, Liège, Sint-Lambrechts-Woluwe
- Age
- 18 years to 75 years
- People
- 1,250 worldwide
- Run by
- GlaxoSmithKline
See details and how to joinNCT07221188 · EU 2025-523674-16-00 - No phaseTaking peopleTargeting the Skeletal Muscle to Treat Metabolic Dysfunction-associated Steatotic Liver Disease
- Where
- Brussels, Louvain-la-Neuve
- Age
- 18 years to 70 years
- People
- 60
- Run by
- Cliniques universitaires Saint-Luc- Université Catholique de Louvain
See details and how to joinNCT06506513 - Phase 1Taking peopleA Study to Test How Well Different Doses of BI 3804379 Are Tolerated by Healthy People and Patients With Metabolic Dysfunction-associated Steatohepatitis (MASH)
- Where
- Edegem
- Age
- 18 years to 65 years
- People
- 124
- Run by
- Boehringer Ingelheim
See details and how to joinNCT06575400 - No phaseTaking peoplePrevalence of NAFLD in T1DM Patients
- Where
- Genk
- Age
- 18 years and over
- People
- 138
- Run by
- Ziekenhuis Oost-Limburg
See details and how to joinNCT06445361